| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6054482 | VIATRIS | Lactam-free amino acids |
Apr, 2017
(7 years ago) | |
|
US6054482 (Pediatric) | VIATRIS | Lactam-free amino acids |
Oct, 2017
(6 years ago) | |
| US7256216 | VIATRIS | Liquid pharmaceutical compositions |
May, 2022
(1 year, 10 months ago) | |
|
US7256216 (Pediatric) | VIATRIS | Liquid pharmaceutical compositions |
Nov, 2022
(1 year, 4 months ago) | |
Neurontin is owned by Viatris.
Neurontin contains Gabapentin.
Neurontin has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Neurontin are:
- US6054482
- US6054482*PED
- US7256216
- US7256216*PED
Neurontin was authorised for market use on 02 March, 2000.
Neurontin is available in capsule;oral, tablet;oral, solution;oral dosage forms.
The generics of Neurontin are possible to be released after 28 November, 2022.
Drugs and Companies using GABAPENTIN ingredient
Market Authorisation Date: 02 March, 2000
Treatment: NA
Dosage: SOLUTION;ORAL; TABLET;ORAL; CAPSULE;ORAL
How can I launch a generic of NEURONTIN before it's drug patent expiration?
More Information on Dosage
NEURONTIN family patents
